#Ireland #Dublin #LUMA Vision #VERAFEYE™ #CardioFocus

LUMA Vision's Groundbreaking Cardiac Innovations

In a significant stride towards advanced cardiac care, LUMA Vision Ltd., renowned for its expertise in 4D navigation and imaging, has announced the successful execution of 15 VERAFEYE™-guided persistent atrial fibrillation (AF) ablation procedures. This achievement, part of a collaborative clinical study with CardioFocus, Inc., showcases the transformative potential of the VERAFEYE™ platform.

The VERAFEYE™ system is engineered to enhance the quality and efficiency of ablation procedures, which are critical in treating conditions like atrial fibrillation. Its utility lies in its ability to integrate high-resolution intracardiac imaging with a dynamic, four-dimensional view of the heart, granting clinicians real-time insights during complex interventions. This innovative approach facilitates pulmonary vein isolation and posterior wall isolation, among other essential procedures, using the highly regarded CardioFocus QuickShot™ Nav pulsed field ablation (PFA) catheter system.

Dr. Ante Anic, Director of Electrophysiology at KBC Split in Croatia, expressed enthusiasm about the efficiency afforded by the VERAFEYE™ system. He noted, “Using an empirical lesion set in the persistent AF population is ideal. The system's unique method for 3D geometry generation allowed me to operate with only one catheter for imaging, navigation, and Rapid Digital Anatomy (RDA). This is truly unparalleled.” The use of this innovative two-catheter approach can lead to completing procedures in less than an hour, emphasizing a new benchmark in procedural efficiency.

Fionn Lahart, CEO of LUMA Vision, highlighted the company's aspirations for this technology: “Our mission is to enhance precision, efficiency, and accuracy in cardiac procedures, aiming for the best possible outcomes for patients. The VERAFEYE system, powered by advanced AI and machine learning, sets a new standard in cardiac care.” This innovative platform not only guides AF therapy with clarity but also opens avenues for future interventions, potentially including left atrial appendage closure and various structural heart procedures.

The remarkable results from the ablation procedures underscore the platform’s capability to lessen procedural times while improving anatomical accuracy and minimizing complications. By continuously delivering an accurate, interactive view of a beating heart during procedures, clinicians can refine their approaches, enhancing patient safety and care outcomes.

The Road Ahead for LUMA Vision

Founded amidst a vision to revolutionize cardiac care, LUMA Vision is based in Dublin, Ireland, with significant operations extending to Munich, Germany. The company is steadfast in its commitment to developing next-generation visualization and navigation systems that empower healthcare professionals with high-definition insights necessary for effective interventions in electrophysiology and structural heart treatments.

As LUMA Vision anticipates expanding the VERAFEYE™ technology into a global market in 2026, the clinical implications of these advancements are poised to be profound. The sustained focus on innovation, as demonstrated by the successful completion of these ablation procedures, places LUMA Vision at the forefront of medical technology solutions for cardiac care.

For those interested in learning more about LUMA Vision’s offerings and future innovations, further details can be accessed through their official website at www.lumavision.com.